Metrics to compare | HELP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipHELPPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.6x | −2.8x | −0.4x | |
PEG Ratio | −0.35 | −0.07 | 0.00 | |
Price/Book | 3.2x | 4.6x | 2.6x | |
Price / LTM Sales | - | 39.0x | 3.1x | |
Upside (Analyst Target) | - | 51.4% | 48.9% | |
Fair Value Upside | Unlock | −3.3% | 6.2% | Unlock |
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company’ preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.